Table 1 Subjects included in the proteomic study. The neuropathological assessment was performed according to Thal phases, CERAD score, NIA-AA guidelines and PART criteria. Aβ immunopositivity was scored on a 4-tiered scale as: (−) negative, (+) 1–2 isolated Aβ depositions, (++) 3–4 Aβ depositions, and (+++) >4Aβ depositions. Graduation of phospho-TAU deposit: (−) negative +: low; ++: intermediate; +++high. PMI: post-mortem interval; n.d: not determined; MP: Mature plaques; DP: Diffuse plaques; v.d: vascular disease.
Cases | age | sex | Duration | Brain | PMI | Pathological diagnosis | IHQ: Aβ in OB | IHQ: TAU in OB | ||
|---|---|---|---|---|---|---|---|---|---|---|
(years) | weight (g) | (hours) | (NIA-AA) criteria | MP | DP | Tangles | neurites | |||
Advanced AD | ||||||||||
BCN349 | 70 | M | 4 | 1104 | 2,5 | AD (A3B3C3) | ++ | +++ | ++ | +++ |
BCN367 | 89 | M | 13 | 1015 | 3 | AD (A2B3C3) | + | +++ | +++ | +++ |
BCN369 | 86 | M | 8 | 973 | 2,5 | AD (A3B3C3) | + | − | + | ++ |
BCN376 | 93 | M | 3 | 1050 | 2,4 | AD (A3B3C3) | + | +++ | +++ | +++ |
intermediate AD | ||||||||||
BCN0104 | 85 | M | 12 | 1115 | 3,3 | AD (A2B2C2) | − | + | +++ | +++ |
BCN0136 | 97 | F | 9 | 900 | n.d | AD (A2B2C2) | n.d | n.d | n.d | n.d |
BCN381 | 77 | M | 17 | 1103 | 1,5 | AD (A2B2C1) | − | − | ++ | ++ |
BCN222 | 86 | F | 9 | 1000 | 3 | AD (A2B2C2) | − | + | ++ | ++ |
Initial AD | ||||||||||
BCN342 | 88 | M | 1 | 1400 | 3,45 | AD (A2B1C2) | ++ | + | ++ | ++ |
BCN336 | 85 | F | 8 | 1130 | 2 | AD (A2B1C1) | − | − | + | + |
BCN358 | 80 | M | 5 | 1090 | 3 | AD (A2B1C1) | ++ | ++ | ++ | +++ |
A12/0046 | 75 | F | n.d | 1125 | 6 | AD (A1B1C1) | − | − | + | + |
A12/0067 | 72 | F | n.d | 810 | 4 | AD (A1B1C1) | − | − | + | + |
Control | ||||||||||
BCN362 | 72 | M | 1407 | 9 | Thal 1 Cerad 1 no tau deposit | − | − | − | + | |
BCN283 | 99 | M | 992 | 3 | No protein deposit+v.d | − | − | − | + | |
BCN387 | 81 | F | 1176 | 3,3 | PART (Braak I)+v.d | − | − | − | + | |
